Dive into each service Altasciences provides as it relates to drug development for small molecules, elucidating how they can support and guide teams at every step.

Developing and manufacturing drugs for preclinical testing marks a crucial initial phase preceding human trials. Delve into the essential considerations for preclinical formulation aimed at safety assessment.

With nine facilities across North America, explore our integrated, comprehensive solution for all your early-phase drug development needs and unique expertise.

Learn how by partnering with Altasciences, pharmaceutical and biotechnology companies can benefit from their expertise and experience to bring better drugs to market more quickly.

Explore the potential of liquid-filled hard-shell capsules to transform formulation challenges into simple solutions and the benefits they offer patients.

Sponsors always ask, “Will the partnership save me time and money?” and “How can you streamline the complex development processes for me?” Get the answers to these questions and more.

Whether you're initiating preclinical safety testing or commencing Phase 1 clinical trials, Altasciences’ manufacturing services can support you from formulation through to commercialization.

Use this resource to decide whether tablets or liquid-filled, hard-shell capsules align seamlessly with the specific requirements of an active pharmaceutical ingredient and desired trial outcomes.

Learn about the multifaceted benefits of liquid-filled capsules and what makes them a versatile and efficient solution in pharmaceutical development.

Review this approach to the manufacture of a nano-milled suspension of loteprednol etabonate intermediate, encompassing the entire product development spectrum and repeat client engagement.

Aiming to obtain a target particle size to support Phase 3 clinical trials, uncover how this study contributed insights on nanosuspension drug product production at escalated scales.

Unearth how Altascienes manages procurement logistics, manufactures the product, performs analytical testing, and terminally sterilizes it for final delivery.

Review alternative oral formulations that have the potential to match or improve upon the PK profile of oral CBD in the fastest and most cost-effective manner possible.

This investigation highlights the strategic use of nanotechnology to overcome formulation challenges and optimize the therapeutic potential of the drug in preparation for clinical trials.

Follow the journey of a prominent cancer therapeutics developer who faced persistent manufacturing challenges with liquid-filled capsules, and how they overcame product and monetary losses.

Offering customization options and opening new marketing avenues, learn more about how liquid-filled hard-shell capsules stand as a versatile solution propelling drug development programs forward.

In this comprehensive exploration, the authors address the complexities inherent in HPAPI manufacturing, encompassing an examination of relevant guidance, classification systems, and safety protocols.

Understand how early engagement with a fully integrated and experienced CNS drug development partner can accelerate timelines by facilitating continuous data sharing and decision-making.

Explore the versatility and significance of LFHCs in pharmaceutical and nutraceutical delivery, as well as their role in enhancing drug solubility, bioavailability, and overall efficiency.

Explore the reasons why this highly complex process requires a unique level of CDMO expertise that can only be gained through extensive experience with developing a broad range of APIs.

Discover the advantages of LFHCs, including improved solubility and bioavailability, enhanced stability, and customizable release profiles, and how they can accelerate drug development timelines.

Learn how CROs and CDMOs work in tandem to address operational and regulatory challenges for pharmaceutical and biotech companies, and how this can determine study success or failure.

Learn more about the benefits of nanomilling, types of milling media and stabilizers, and scale up for clinical manufacturing.

Drug development in the ocular space has specific challenges. Explore how an end-to-end solution can facilitate a path to Phase 2.